Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, red cell, surgical, and plasma collection products. This report covers the quarter and six months ended September 28, 2002 (Fiscal Year 2003). The company operates globally, with approximately 62% of revenues generated outside the United States.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 28, 2002 | 3 Months Ended Sep 29, 2001 | 6 Months Ended Sep 28, 2002 | 6 Months Ended Sep 29, 2001 |
|---|---|---|---|---|
| Net Revenues | $87,025 | $80,704 | $168,960 | $156,505 |
| Gross Profit | $38,890 | $39,801 | $77,537 | $76,112 |
| Gross Margin | 44.7% | 49.3% | 45.9% | 48.6% |
| Operating Income | $9,826 | $12,954 | $19,518 | $22,486 |
| Net Income | $6,780 | $9,948 | $13,555 | $19,892 |
| Diluted EPS | $0.27 | $0.37 | $0.53 | $0.73 |
| Cash from Operations (6mo) | $12,057 (vs $17,080 prior year) | |||
| Cash & Short-term Investments | $43,615 (as of Sep 28, 2002) | |||
| Total Debt (Current + Long-term) | $78,888 (as of Sep 28, 2002) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.8% for the quarter and 8.0% for the six-month period. On a constant currency basis, growth was 8.6% and 9.8% respectively. Growth was driven by Red Cell (+34.0% Q/Q, +39.8% 6mo/6mo) and Plasma (+4.9% Q/Q, +5.8% 6mo/6mo) disposables, partially offset by a decline in Blood Bank disposables (-5.5% Q/Q, -4.0% 6mo/6mo).
- Margin Compression: Gross margin decreased to 44.7% from 49.3% in the prior year quarter. This was due to a higher mix of equipment sales (which have lower margins) and a manufacturing provision for quality enhancements to the OrthoPAT(R) system, despite cost reductions from the "CORE" program.
- Operating Income: Operating income declined 24.1% for the quarter and 13.2% for the six-month period, primarily due to the gross margin compression and increased selling, general, and administrative expenses related to new product marketing.
- Cash Flow: Operating cash flow decreased $5.0 million year-over-year for the six-month period, largely due to lower net income and increased investment in working capital (accounts receivable and inventory).
Guidance, Outlook, and Risks
- Tax Outlook: Management anticipates an effective tax rate of approximately 27% for the full fiscal year 2003, expecting a favorable resolution to tax contingencies in the third quarter. The fourth quarter rate is estimated at 36.0%.
- Product Outlook: Growth in the OrthoPAT(R) surgical business is expected to level off temporarily for the remainder of the fiscal year. Equipment sales are noted as variable with no assurance of continued significant increases.
- Capital Allocation: The company completed a $26.0 million share repurchase program in Q1 and authorized an additional $50 million in July 2002. In Q2, they repurchased an additional $15.0 million of stock.
- Contingencies: The company has contingent obligations of up to $4.1 million for the Fifth Dimension acquisition earn-out and up to $14.5 million in milestone payments for pathogen inactivation technology with Baxter Healthcare.
- Market Risks: Significant exposure to foreign exchange rates (Euro and Yen). A 10% strengthening of the U.S. dollar would increase the fair value of forward contracts by $10.1 million, while a 10% weakening would decrease it by $11.5 million.
Investor Verification Checklist
- Verify the sustainability of Red Cell and Plasma sales growth given the specific regulatory drivers (blood shortages, donor deferrals) cited.
- Monitor the impact of the OrthoPAT(R) quality provision on future gross margins and the timeline for the "CORE" cost reduction program.
- Assess the timing and likelihood of the $14.5 million in milestone payments to Baxter Healthcare.
- Review the company's foreign exchange hedging strategy effectiveness given the 62% international revenue exposure.
- Track the execution of the new $50 million share repurchase authorization and its impact on liquidity.